ArticleScientific reports2025
Epidemiologic features and economic burden of Wilson's disease in South Korea: a nationwide analysis of the entire patient population.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gene therapy for liver diseases: methods, challenges and opportunities.Journal of nanobiotechnology · 2026Review
- Analysis of oral health status and factors influencing DMFT scores in patients with Wilson's disease: a cross-sectional study.BMC oral health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wilson's disease (WD) is a rare genetic disorder causing copper accumulation in the liver, brain, and other organs, causing severe health complications. While studies have assessed WD's economic impact, research on the financial burden of its complications remains limited. This study examines both the epidemiological characteristics and socioeconomic burden of WD by complication type using an all-cause cost-of-illness approach with 2019 claims data from the National Health Insurance Service of South Korea (NHIS). Among 1462 patients (prevalence: 0.028 per 1,000), complications were present in 68.7%, with hepatic (55.8%) being most common, followed by neurological (16.8%), psychiatric (13.9%), and hematological (6.8%). Disabilities affected 21.5% of patients, with 54.5% classified as severe. Annual hospitalization rates were 6.44% for WD-related and 19.36% for all-cause admissions, with WD-related hospitalizations averaging 4.38 per patient. Medication adherence was low (53.4% mean medication possession ratio). The societal perspective, the all-cause per-capita cost was $6297, totaling $9.21 million nationally. Neurological complications increased costs by 1.84 times, psychiatric by 1.64, and disabilities by 1.66. WD imposes a substantial socioeconomic burden in South Korea, primarily due to neurological and psychiatric complications and high hospitalization rates. Targeted prevention and effective management of these complications are essential to reduce costs and improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.